# rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter

> **NCT00145366** · PHASE2 · COMPLETED · sponsor: **Odense University Hospital** · enrollment: 110 (—)

## Conditions studied

- Benign Nontoxic and Toxic Goiter
- Graves' Disease

## Interventions

- **DRUG:** Recombinant human thyrotropin (Thyrogen)

## Key facts

- **NCT ID:** NCT00145366
- **Lead sponsor:** Odense University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** —
- **Final completion:** 2005-07
- **Target enrollment:** 110 (—)
- **Last updated:** 2010-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00145366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00145366, "rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00145366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*